Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Portfolio Pulse from Vandana Singh
Moderna has submitted an FDA application for its updated COVID-19 vaccine targeting the JN.1 variant for the 2024-2025 season. Novavax expects to deliver its JN.1 vaccine by September, pending authorization. Pfizer/BioNTech and Moderna plan to have their updated vaccines available this fall.
June 07, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer/BioNTech plan to have their updated COVID-19 vaccines available this fall ahead of the 2024-2025 flu season.
Pfizer/BioNTech's plan to have their updated vaccines available this fall aligns with regulatory guidance and could positively impact their stock price as they meet market demand.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Moderna has submitted an FDA application for its updated COVID-19 vaccine targeting the JN.1 variant for the 2024-2025 season.
The submission of the FDA application is a significant step for Moderna, indicating progress in their vaccine development. This could positively impact their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Novavax expects to be ready for the commercial delivery of its JN.1 COVID-19 vaccine in the U.S. by September, pending authorization.
Novavax's readiness to deliver its JN.1 vaccine by September, pending authorization, is a positive development that could boost investor confidence and positively impact the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Pfizer/BioNTech plan to have their updated COVID-19 vaccines available this fall ahead of the 2024-2025 flu season.
Pfizer/BioNTech's plan to have their updated vaccines available this fall aligns with regulatory guidance and could positively impact their stock price as they meet market demand.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70